oxaliplatin
Showing 1 - 25 of 921
Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)
Not yet recruiting
- Immunotherapy Gastrict Cancer
- Tislelizumab
- +3 more
- (no location specified)
Jan 17, 2023
Advanced Gastric Carcinoma Trial in Dhaka (Trastuzumab, Oxaliplatin, Capecitabine)
Completed
- Advanced Gastric Carcinoma
- Trastuzumab
- +2 more
-
Dhaka, BangladeshBangabandhu Sheikh Mujib Medical University
Aug 15, 2023
Gastric Cancer Trial in Beijing (Apatinib, Oxaliplatin, S1)
Recruiting
- Gastric Cancer
- Apatinib
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023
Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)
Recruiting
- Immunotherapy
- Gastrict Cancer
- Tislelizumab
- +3 more
-
Fuzhou, ChinaFujian cancer hospital
Jan 17, 2023
Malignant Digestive System Tumor Trial in Atlanta (Fluorouracil, Leucovorin, Oxaliplatin)
Recruiting
- Malignant Digestive System Neoplasm
- Fluorouracil
- +2 more
-
Atlanta, Georgia
- +2 more
Dec 12, 2022
Gastric Cancer Stage IV Trial (Oxaliplatin, Levo-Leucovorin, 5-fluorouracil)
Not yet recruiting
- Gastric Cancer Stage IV
- Oxaliplatin
- +5 more
- (no location specified)
Nov 13, 2022
Biliary Cancer, Bile Duct Cancer, Cancer of the Bile Duct Trial run by the National Cancer Institute (NCI) (oxaliplatin,
Not yet recruiting
- Biliary Cancer
- +2 more
- oxaliplatin
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
May 13, 2023
Stage III Colon Cancer Trial in France (Oxaliplatin, Oxaliplatin LBM)
Active, not recruiting
- Stage III Colon Cancer
- Oxaliplatin
- Oxaliplatin LBM
-
Marseille, Bouches Du Rhône, France
- +10 more
Aug 2, 2022
Gastric Cancer Trial in Beijing (S-1, Trastuzumab, Oxaliplatin)
Completed
- Gastric Cancer
- S-1
- +3 more
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences
Aug 14, 2022
Elderly Metastatic Colorectal Cancer Patients Trial in Padua (Capecitabine, Oxaliplatin, Bevacizumab)
Active, not recruiting
- Elderly Metastatic Colorectal Cancer Patients
- Capecitabine
- +2 more
-
Padua, ItalyIstituto Oncologico Veneto IRCCS
Mar 30, 2022
Colorectal Adenocarcinoma, Mucinous Adenocarcinoma, Signet Ring Cell Adenocarcinoma Trial in Trondheim, Lørenskog, Oslo
Not yet recruiting
- Colorectal Adenocarcinoma
- +2 more
- Nivolumab
- Oxaliplatin
-
Trondheim, Trondelag, Norway
- +2 more
Aug 15, 2022
Gastric Cancer Trial in Gyeonggi-do (Oxaliplatin, Capecitabine)
Recruiting
- Gastric Cancer
- Oxaliplatin
- Capecitabine
-
Gyeonggi-do, Korea, Republic ofHallym University Medical Center
Feb 4, 2022
Gastric Cancer, Stomach Cancer, GastroEsophageal Cancer Trial in Kyiv (Docetaxel, Oxaliplatin, Leucovorin)
Recruiting
- Gastric Cancer
- +10 more
- Docetaxel
- +3 more
-
Kyiv, UkraineNational Cancer Institute
Aug 31, 2023
Gastric Cancer Trial in Mykolaiv (Docetaxel, Oxaliplatin, Leucovorin)
Active, not recruiting
- Gastric Cancer
- Docetaxel
- +4 more
-
Mykolaiv, UkraineUkrainian Society of Clinical Oncology
Apr 11, 2022
Hepatocellular Carcinoma Resectable Trial in Guangzhou (Oxaliplatin, Doxorubicin, Lobaplatin)
Recruiting
- Hepatocellular Carcinoma Resectable
- Oxaliplatin
- +5 more
-
Guangzhou, Guangdong, ChinaZhujiang Hospital of Southern Medical University
Mar 1, 2023
Colorectal Tumors Trial in Philadelphia (bevacizumab, cetuximab, Oxaliplatin)
Terminated
- Colorectal Neoplasms
- bevacizumab
- +3 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Dec 30, 2021
Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)
Recruiting
- Colonic Neoplasms
- +2 more
- Tislelizumab
- +3 more
-
Nanning, Guangxi, ChinaThe First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023
Gastric Cancer Trial in Jinan (SHR1210, Apatinib, S1)
Recruiting
- Gastric Cancer
- SHR1210
- +3 more
-
Jinan, Shandong, ChinaQilu hospital of Shandong univertisy
Mar 30, 2022
Biliary Tract Tumor Trial in Nanjing (Tislelizumab, Lenvatinib, Oxaliplatin)
Recruiting
- Biliary Tract Tumor
- Tislelizumab
- +3 more
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital
Mar 14, 2022
Liver, Cancer of, Primary Resectable Trial in Guangzhou (Oxaliplatin, Doxorubicin, Lobaplatin)
Recruiting
- Liver, Cancer of, Primary Resectable
- Oxaliplatin
- +5 more
-
Guangzhou, Guangdong, ChinaZhujiang Hospital of Southern Medical University
Jan 18, 2023
Phase II, Open-label, Parallel 2-arm, Multi-center Trial in Kaohsiung, Taichung, Tainan (Gemcitabine 1000 mg, Nab paclitaxel,
Recruiting
- Phase II, Open-label, Parallel 2-arm, Multi-center
- Gemcitabine 1000 mg
- +4 more
-
Kaohsiung, Taiwan
- +2 more
Jun 12, 2022